Inborn Errors of Metabolism

Andres Corado; Haseena Sait; Manan Shah

Inborn Errors of Metabolism

Author: Andres Corado Author: Haseena Sait Editor: Manan Shah Updated: 8/7/2026 9:43:35 AM

Introduction

Traditionally, inborn errors of metabolism (IEMs) were considered a group of monogenic disorders caused by defects in the synthesis or catabolism of molecules within specific metabolic pathways, leading to a deficiency of essential products or the accumulation of toxic substrates, resulting in measurable abnormalities on classic biochemical laboratory testing.[1] However, the recently proposed nosology defines IEMs as conditions that disrupt metabolic pathways, regardless of the presence of detectable biochemical abnormalities. Using this extended definition, 1015 well-characterized IEMs in 130 groups have been described.[2]

Additionally, although individual disorders are rare, collectively, IEMs are significant, with an estimated global birth prevalence of 50.9 per 100,000 live births and the highest reported rates in the Eastern Mediterranean region.[3] The clinical presentation ranges from acute, catastrophic metabolic crises in the neonatal or infantile period to chronic, progressive multisystem involvement or predominantly neuropsychiatric presentations in adolescence or adulthood. IEMs represent a significant cause of global childhood morbidity and mortality; therefore, early diagnosis and timely interventions are critical.

Etiology

Register For Free And Read The Full Article

Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.

Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities

Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

IEMs are inherited genetic disorders caused by defects in single genes that encode proteins necessary for metabolic pathways. These defects can involve enzymes, membrane transporters, or cofactors, causing a metabolic block.

Inheritance Patterns

Autosomal recessive: The autosomal recessive pattern is the most common mode of inheritance for IEMs. Both parents must carry the genetic defect.
X-linked: Mutations on the X chromosome commonly affect males, although females can also be affected to varying degrees. Examples include ornithine transcarbamylase deficiency, Hunter syndrome (mucopolysaccharidosis type 2 [MPS 2]), and Fabry disease.
Autosomal dominant: Autosomal dominant inheritance is a rare cause of IEMs because a single defective copy of a gene is sufficient to cause the disorder. Examples include acute intermittent porphyria and certain types of familial hypercholesterolemia.
Mitochondrial inheritance: Disorders affecting mitochondrial DNA are transmitted maternally to all offspring. Examples include mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and myoclonic epilepsy with ragged red fibers.

A single-gene defect impairs the function of a specific enzyme or transport protein. Epigenetic modifications can significantly influence phenotypic expression and disease severity. Environmental factors, such as infection or nutritional status, can also modify these characteristics.[4]

Epidemiology

While individually rare, IEMs are collectively common, with an estimated global birth prevalence of 50.9 per 100,000 live births (approximately 1 in 2000). However, the incidence varies significantly by region and can be as high as 75.7 per 100,000 live births (1 in 1321) in the Eastern Mediterranean region due to high parental consanguinity rates. Results from studies showed higher incidence rates, sometimes as high as 1 in 377, in high-risk hospitalized populations.[5] Among disorders with the highest birth prevalence, amino acidurias (most commonly phenylketonuria) rank first, followed by lysosomal storage disorders. The case fatality rates of IEMs appear to be 33% or higher in resource-limited countries, and account for 0.4% of all child deaths worldwide.[3] Moreover, although traditionally regarded as disorders of infancy and early childhood, IEMs are increasingly recognized during adolescence and adulthood. Results from global epidemiological studies conducted over the past 15 years indicated that approximately 16% to 37% of IEM diagnoses are made in individuals older than 10 years.[6][7]

Pathophysiology

A recent simplified classification of IEMs that combines clinical, diagnostic, and pathophysiological approaches has been proposed by Saudubray and colleagues.[8] The classification aligns with the most recent nosology of IEMs and categorizes disorders into three broad groups based on the size of the involved molecules (small or complex) and their role in energy metabolism.[2] The 3 groups are described below.

Group 1: Disorders of Small Molecules

These disorders are broadly divided into 2 subcategories: accumulation disorders and deficiency disorders.

Accumulation disorders: Accumulation disorders result from the accumulation of toxic small molecules and typically do not interfere with embryonic or fetal neurodevelopment. Affected individuals usually present after a symptom-free interval ranging from days to years with acute, intermittent, chronic, or progressive intoxication-like manifestations, often precipitated by fasting, fever, intercurrent illness, or dietary intake. Plasma or urine metabolic biomarkers are usually readily measurable, and these disorders are often treatable; therefore, early recognition is essential. The subgroup includes disorders of amino acid catabolism, such as phenylketonuria and maple syrup urine disease; urea cycle disorders; organic acidurias; galactosemia; metal accumulation disorders, such as Wilson disease; and certain purine, pyrimidine, and vitamin metabolism disorders.

Deficiency disorders: Deficiency disorders arise from impaired synthesis of essential compounds distal to a metabolic block or defective transport of essential molecules across cellular membranes. Clinically, they share several features with disorders of complex molecules, frequently affecting neurodevelopment and often presenting antenatally or congenitally with structural anomalies. The subgroup includes transporter defects involving essential molecules; disorders affecting neurotransmitter metabolism; disorders of nonessential amino acid and fatty acid synthesis; metal deficiency disorders; and several disorders of pyrimidine metabolism. Some of these conditions are potentially treatable.

Group 2: Disorders of Complex Molecules

Group 2 disorders affect the metabolism of complex molecules that are neither water-soluble nor diffusible. Clinical manifestations are usually permanent, progressive, and independent of intercurrent illness or food intake. Most disorders in the group do not present with acute metabolic crises. Group 2 disorders are broadly classified into 3 subcategories.

Accumulation disorders of complex molecules: These disorders result from the storage or accumulation of compounds within the cytoplasm (eg, glycogen storage disorders or steatosis) or lysosomes, as seen in lysosomal storage disorders. The subgroup includes glycogen storage disorders, sphingolipidoses, mucopolysaccharidoses, glycoproteinoses, and neutral lipid storage disorders. Affected individuals commonly present with multisystem involvement associated with progressive neurodegeneration. Antenatal manifestations are generally absent, although severe forms may present with hydrops fetalis or congenital malformations. Several disorders in the group have established or emerging therapeutic options.

Deficiency disorders of complex molecules: These disorders arise from defective synthesis or recycling of complex molecules in organelles. The subgroup includes glycogen depletion syndromes; disorders of phospholipid, glycosphingolipid, and fatty acid synthesis and remodeling; peroxisomal disorders; cholesterol and bile acid synthesis defects; glycosaminoglycan synthesis disorders; and nucleic acid metabolism disorders. Clinically, these conditions are characterized by multisystem involvement, neurodegeneration with prominent motor manifestations, and frequent antenatal or congenital malformations. Most disorders in the subgroup currently lack definitive treatment options.

Cellular trafficking and processing disorders: The subgroup includes congenital disorders of glycosylation, synaptic vesicle cycle disorders, aminoacyl-transfer RNA synthetase deficiencies, and disorders of intracellular vesiculation, trafficking, processing, and quality control processes, including protein folding and autophagy. Clinically, these disorders are characterized by multisystem involvement with prominent neurological manifestations and may phenotypically mimic mitochondrial and lysosomal storage disorders. Most conditions in the subgroup currently lack specific therapeutic options.

Group 3: Disorders Primarily Involving Energy Metabolism

Group 3 comprises IEMs in which clinical manifestations result, at least in part, from impaired energy production or use in tissues with high energy demands, such as the brain, liver, myocardium, and skeletal muscle. These disorders are subdivided into 3 major categories.

Disorders of membrane carriers of energy-related molecules: These disorders include defects in the transport of energy-related substrates across cellular membranes, such as glucose transporter defects and monocarboxylate transporter deficiencies. Several disorders in the subgroup are treatable or partially treatable.

Cytoplasmic energy defects: These disorders generally have a comparatively mild phenotype and include defects in glycolysis, glycogen metabolism, and the pentose phosphate pathway. Conversely, mitochondrial energy defects may cause clinically heterogeneous presentations.

Mitochondrial energy defects: The subgroup includes disorders affecting aerobic glucose oxidation and mitochondrial energy production, such as congenital lactic acidemia, mitochondrial respiratory chain disorders, defects in mitochondrial transporters, defects in coenzyme Q biosynthesis, fatty acid oxidation disorders, and defects in ketone body metabolism. Certain thiamine- and riboflavin-responsive disorders are also included. These conditions may present at any age and manifest as tissue-specific or multisystem disorders, predominantly affecting organs with high energy requirements.

History and Physical

The history and physical examination provide important clues to the diagnosis of an IEM. The clinical presentation often depends on age and may range from antenatal abnormalities and acute metabolic decompensation in the neonatal period to chronic, progressive neurological or multisystem disease presenting later in life. Clinicians should maintain a high index of suspicion in patients with unexplained encephalopathy, episodic deterioration precipitated by catabolic stressors, recurrent or refractory symptoms, developmental regression, multisystem involvement, or a suggestive family history.

History

Antenatal and congenital presentation: Although uncommon, some IEMs may present antenatally with fetal growth abnormalities, nonimmune hydrops fetalis, polyhydramnios, reduced fetal movements, hepatosplenomegaly, renal cysts, skeletal dysplasia, congenital malformations, or characteristic brain abnormalities detected on fetal imaging.[9]

Neonatal and infantile presentation: Neonatal IEMs commonly present with nonspecific manifestations such as poor feeding, lethargy, vomiting, hypotonia, respiratory distress, seizures, or jaundice, thereby mimicking neonatal sepsis. A characteristic feature of many intoxication-type disorders is rapid deterioration following an initial symptom-free interval, particularly after initiation of feeds, prolonged fasting, fever, or intercurrent illness. Additional clues include rapidly progressive encephalopathy, recurrent unexplained metabolic decompensation, failure to respond to standard therapy, peculiar body odor, and intractable hiccups.

Childhood presentation: In childhood, IEMs should be suspected in patients presenting with unexplained recurrent, refractory, episodic, or progressive neurological or multisystem manifestations, particularly when precipitated by fasting, intercurrent illness, prolonged exercise, or other catabolic stressors. Important clinical clues include developmental delay or regression, intellectual disability, learning difficulties, recurrent altered sensorium, persistent or recurrent vomiting, abnormal movements, refractory seizures, exercise intolerance, muscle cramps, and fatigue.

Adolescent and adult presentation: Late-onset IEMs frequently manifest predominantly as unexplained neurological, psychiatric, or neuromuscular disorders. Clinical suspicion should be raised in patients with fluctuating symptoms triggered by fasting, fever, a surgical procedure, exercise, the postpartum period, high-protein intake, or certain medications. Neurological manifestations may include encephalopathy, stroke-like episodes, movement disorders, peripheral neuropathy, spastic paraparesis, epilepsy, psychiatric symptoms, or recurrent rhabdomyolysis.[10][11]

Family history: A detailed family history is essential and should include parental consanguinity, unexplained sibling deaths, recurrent miscarriages, sudden infant death syndrome, similarly affected family members, developmental disabilities, or unexplained neurodegenerative disorders in relatives.

Physical Examination

Physical examination findings in patients with IEMs are often multisystem. The findings vary with age at presentation and the underlying metabolic defect. Tables 1 to 3 summarize phenotype-based clinical clues and common differential diagnoses across different age groups.

Table 1. Antenatal and Congenital Differential Diagnosis of Inborn Errors of Metabolism

System	Clinical presentation	Most common differential diagnosis
General	Nonimmune hydrops fetalis	Lysosomal storage disorder (Niemann-Pick disease type C, mucolipidosis type 2), mucopolysaccharidosis type 7, glycogen storage disease type 4, congenital disorders of glycosylation, Wolman disease
Facial profile	Binder phenotype and flat facies	Mucopolysaccharidosis type 7, peroxisomal biogenesis disorders, chondrodysplasia punctata
Growth	Intrauterine growth restriction	Smith–Lemli–Opitz syndrome, mitochondrial disorders
	Overgrowth	Congenital hyperinsulinism
Renal	Echogenic kidneys	Peroxisomal biogenesis disorders, congenital disorders of glycosylation
	Cysts	Peroxisomal biogenesis disorders (Zellweger syndrome), fatty acid oxidation defects (multiple acyl-coenzyme A dehydrogenase deficiency, carnitine palmitoyltransferase type 2 deficiency)
Gastrointestinal	Hepatosplenomegaly	Lysosomal storage disorders (Niemann–Pick disease type C, Gaucher disease type 2, sialic acid storage disease, galactosialidosis, sialidosis type 2, mucopolysaccharidosis type 7)
	Hyperechogenic colon	Cystinuria
	Adrenal calcifications	Wolman disease
Central nervous system	Germinolysis cysts	Peroxisomal biogenesis disorders, glutaric aciduria type 1
	Polymicrogyria	Peroxisomal biogenesis disorders
	Cobblestone lissencephaly	Congenital disorders of O-mannosylglycan synthesis
	Corpus callosum dysgenesis	Carnitine palmitoyltransferase type 2 deficiency, Smith–Lemli–Opitz syndrome, nonketotic hyperglycinemia, pyruvate dehydrogenase deficiency, ALG3-congenital disorder of glycosylation, sulfite oxidase deficiency, and molybdenum cofactor deficiency
	Pontocerebellar hypoplasia	PMM2-congenital disorders of glycosylation
	Microcephaly	Inborn errors of serine metabolism and asparagine synthetase deficiency, Smith–Lemli–Opitz syndrome, maternal phenylketonuria
	Craniosynostosis	Disorders of cholesterol synthesis (Antley–Bixler syndrome), mucolipidosis type 2
	Neural tube defects	Folate disorders
Musculoskeletal	Dysostosis	Disorders of cholesterol synthesis (Antley–Bixler syndrome, Greenberg dysplasia), peroxisomal biogenesis disorders
		Smith–Lemli–Opitz syndrome
	Arthrogryposis	Lysosomal storage disorders (Gaucher disease type 2), glycogen storage disease type 4, peroxisomal biogenesis disorders (rhizomelic chondrodysplasia punctata)
	Epiphyseal stippling	Peroxisomal biogenesis disorders (rhizomelic chondrodysplasia punctata, Zellweger spectrum disorder), disorders of cholesterol synthesis (Conradi–Hünermann–Happle syndrome and congenital hemidysplasia with ichthyosiform nevus and extremity defects syndrome), arylsulfatase E deficiency, lysosomal storage disorders (sialidosis, galactosialidosis, sialic acid storage disease, and mucolipidosis type 2)

Abbreviations: ALG3, alpha-1,3-mannosyltransferase gene; PMM2, phosphomannomutase 2 gene.

Table 2. Neonatal and Childhood Differential Diagnosis of Inborn Errors of Metabolism

System	Clinical presentation	Most common differential diagnosis
Central and peripheral nervous systems	Metabolic encephalopathy	Early onset: Maple syrup urine disease; organic acidemias, including methylmalonic acidemia, propionic acidemia, and isovaleric acidemia; multiple carboxylase deficiency; and urea cycle disorders Late onset and intermittent: Fatty acid oxidation defects; disorders of gluconeogenesis; disorders of ketogenesis and ketolysis; and late-onset forms of disorders presenting in the neonatal period
	Predominant seizures	Pyridoxine-responsive seizures, folinic acid–responsive epilepsy, multiple carboxylase deficiency
	Severe hypotonia	Congenital disorders of glycosylation, peroxisomal biogenesis disorders, fatty acid oxidation defects
	Recurrent ataxia	Late onset and intermittent: Maple syrup urine disease; organic acidemias; urea cycle disorders, including ornithine transcarbamylase and argininosuccinate synthetase deficiencies; biotinidase deficiency; and Hartnup disease
	Acute psychiatric manifestations	Late onset and intermittent: Urea cycle disorders, including ornithine transcarbamylase deficiency; acute intermittent porphyria; homocystinuria; and cerebrotendinous xanthomatosis
	Chronic and progressive neurological deterioration	Lysosomal storage disorders, congenital disorders of glycosylation, urea cycle disorders (argininosuccinic aciduria), peroxisomal biogenesis disorders, respiratory chain disorders, biotinidase deficiency, neurotransmitter defects, nonketotic hyperglycinemia
	Predominant intellectual disability	Creatine deficiency, Smith–Lemli–Opitz syndrome
Gastrointestinal	Jaundice and liver failure	Galactosemia, tyrosinemia type 1, hereditary fructose intolerance
	Cholestatic jaundice	Arginase deficiency, galactosemia, tyrosinemia type 1, Niemann–Pick disease type C, bile acid metabolism disorders
	Hepatomegaly and Reye-like syndrome	Fatty acid oxidation defects, urea cycle disorders
	Hepatosplenomegaly	Lysosomal storage disorders, mucopolysaccharidoses, oligosaccharidoses
	Persistent hypoglycemia	Congenital hyperinsulinism, glycogenosis defects, fatty acid oxidation defects
	Recurrent abdominal pain	Urea cycle disorders, acute intermittent porphyria, Fabry disease
	Acute pancreatitis	Organic acidemias, including methylmalonic acidemia, propionic acidemia, isovaleric acidemia, and maple syrup urine disease; lysinuric protein intolerance
	Hemolysis, elevated liver enzymes, and low platelet count syndrome in mothers	Carnitine palmitoyltransferase type 1 deficiency, long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency, respiratory chain disorders
	Inguinal and umbilical hernias	Mucopolysaccharidoses
Cardiovascular	Cardiomyopathies	Lysosomal storage disorders (Fabry disease, mucopolysaccharidoses, Pompe disease), long-chain fatty acid oxidation defects, and some respiratory chain disorders
	Arrhythmias and conduction defects	Long-chain fatty acid oxidation defects
Dermatological	Ichthyosis	Lysosomal storage disorders (Gaucher disease type 2, multiple sulfatase deficiency), Sjögren–Larsson syndrome, serine synthesis defects, cholesterol synthesis defects, organic acidemias (methylmalonic acidemia, biotinidase deficiency, multiple carboxylase deficiency)
	Angiokeratomas	Fabry disease, aspartylglucosaminuria, oligosaccharidoses (β-mannosidosis, fucosidosis, galactosialidosis)
	Hyperkeratosis	Tyrosinemia type 2
	Vesiculobullous lesions and skin rashes	Porphyrias, organic acidemias, Hartnup disease, lysinuric protein intolerance
	Cutis laxa	Copper metabolism defects (Menkes disease), congenital disorders of glycosylation
	Skin ulcers	Prolidase deficiency
Endocrine	Hypothyroidism	Cystinosis, Fabry disease
	Hypoparathyroidism	Long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency
	Growth hormone deficiency	Respiratory chain disorders
	Hypogonadism	PMM2 congenital disorder of glycosylation
Hematological	Macrocytic anemia	Cobalamin metabolism defects
	Pancytopenia	Lysosomal storage disorders (Gaucher disease types 1 and 3, Niemann–Pick disease types A and B), organic acidemias (methylmalonic acidemia, propionic acidemia, isovaleric acidemia), lysinuric protein intolerance
Muscular	Myopathy	Fatty acid oxidation defects, carnitine transporter defect, glycogen storage diseases (types 2, 3, 4, and 5)
	Recurrent myoglobinuria	Glycogen storage disease type 5, fatty acid oxidation defects
Renal	Nephrolithiasis	Cystinuria, hyperoxaluria
	Tubulopathy	Methylmalonic acidemia, glycogen storage disease type 1, carnitine palmitoyltransferase type 1 deficiency
	Polycystic kidney disease	Carnitine palmitoyltransferase type 2 deficiency, glutaric aciduria type 2, congenital disorders of glycosylation, Zellweger syndrome
Ophthalmological	Cataract	Galactosemia, peroxisomal biogenesis disorders, and cholesterol synthesis disorders
	Corneal clouding	Mucopolysaccharidoses, tyrosinemia type 2, cystinosis, mucolipidosis type 2, Wilson disease
Skeletal	Bone dysplasia	Lysosomal storage disorders, cholesterol synthesis disorders
	Punctate epiphyseal calcifications	Cholesterol synthesis disorders
	Bone infarction	Lysosomal storage disorders (Gaucher disease type 1, Farber disease)
Respiratory	Interstitial pneumonia	Lysinuric protein intolerance, lysosomal storage disorders (Gaucher disease, Niemann–Pick disease type B)
	Pulmonary hypertension	Glycogen storage disease type 1
Facial profile	Coarse facies	Mucopolysaccharidoses, oligosaccharidoses
	Binder phenotype and flat facies	Chondrodysplasia punctata, Zellweger syndrome

Early-onset: Presentation during the neonatal period or early infancyLate-onset/intermittent: Presentation beyond infancy

Abbreviations: ALG3, alpha-1,3-mannosyltransferase gene; PMM2, phosphomannomutase 2 gene.

Table 3. Adolescent and Adult Differential Diagnosis of Inborn Errors of Metabolism

System	Clinical presentation	Most common differential diagnosis
Central nervous system	Metabolic encephalopathy with or without focal signs	Maple syrup urine disease, urea cycle disorders, acute intermittent porphyria, homocysteine remethylation defects, nonketotic hyperglycinemia, respiratory chain disorders
	Stroke and stroke-like attacks	Fabry disease, homocystinuria, urea cycle disorders, organic acidemias (methylmalonic acidemia, propionic acidemia, isovaleric acidemia), respiratory chain disorders
	Extrapyramidal symptoms	Organic acidemias (methylmalonic acidemia, glutaric aciduria type 1), respiratory chain disorders, Wilson disease, lysosomal storage disorders (Niemann–Pick disease type C, Gaucher disease, GM1 and GM2 gangliosidoses), neuronal ceroid lipofuscinosis, neurodegeneration with brain iron accumulation
	Seizures	Respiratory chain disorders, lysosomal storage disorders (Gaucher disease type 3, Niemann–Pick disease type C, sialidoses), and acute intermittent porphyria
	Psychiatric disorders	Urea cycle disorders, acute intermittent porphyria, homocysteine remethylation defects, phenylketonuria, Wilson disease, lysosomal storage disorders (GM2 gangliosidosis, Niemann–Pick disease type C, metachromatic leukodystrophy, adrenoleukodystrophy)
	Spastic paraparesis	Cerebrotendinous xanthomatosis, adrenomyeloneuropathy, metachromatic leukodystrophy, phenylketonuria, urea cycle disorders (arginase deficiency), homocysteine remethylation defects
	Cerebellar ataxia	Respiratory chain disorders, glucose transporter type 1 deficiency syndrome, lysosomal storage disorders (Gaucher disease type 3, Niemann–Pick disease type C, GM2 gangliosidoses), vitamin E deficiency, abetalipoproteinemia, urea cycle disorders
Peripheral nervous system	Peripheral neuropathy	Respiratory chain disorders, lysosomal storage disorders (GM2 gangliosidoses, Fabry disease, metachromatic leukodystrophy, Krabbe disease, adrenomyeloneuropathy), tyrosinemia type 1, peroxisomal biogenesis disorders, and acute porphyria
	Myopathy	Mitochondrial disorders, primary carnitine deficiency, glycogen storage diseases (types 2, 3, and 5)
Opthalmological	Eye movement abnormalities	Vertical supranuclear gaze palsy: Niemann–Pick disease type C Horizontal supranuclear gaze palsy: Gaucher disease type 3 Oculogyric crisis: Disorders of dopamine metabolism
	Cataract	Cerebrotendinous xanthomatosis, Wilson disease
	Kayser–Fleischer ring	Wilson disease
	Cherry-red spot	Lysosomal storage disorders
	Retinitis pigmentosa	Mitochondrial disorders
	Optic neuropathy	Mitochondrial disorders, pyruvate dehydrogenase deficiency

Abbreviations: GM1, GM1 gangliosidosis; GM2, GM2 gangliosidosis.

Evaluation

Following a clinical suspicion of IEM in a sick child, laboratory investigations and supportive measures should begin simultaneously. Though not diagnostic by themselves, certain bedside tests can help in quick screening for IEM (Table 4).

Table 4: Initial Laboratory Evaluation in Suspected Inborn Errors of Metabolism

Investigations	Results	Differential diagnosis
Complete blood count	Pancytopenia	Organic acidurias, including methylmalonic acidemia, propionic acidemia, and isovaleric acidemia
	Megaloblastic anemia	Vitamin B₁₂ and cobalamin or folate absorption and intracellular utilization disorders
Urine	Abnormal color	Cola color: Rhabdomyolysis Darkening on standing or exposure to light: Porphyria, alkaptonuria Blue urine: Hartnup disease
	Abnormal odor	Burnt sugar odor: Maple syrup urine disease Sweaty feet: Isovaleric acidemia, glutaric aciduria type 2 Boiled cabbage odor: Tyrosinemia type 1, methionine malabsorption Tomcat urine odor: Multiple carboxylase deficiency Mousy: Phenylketonuria Rotten fish: Trimethylaminuria
Cerebrospinal fluid (CSF)	Abnormal neurotransmitter profiling	Neurotransmitter disorders
	CSF-to-plasma glycine ratio > 0.04	Nonketotic hyperglycemia
Liver function tests	Abnormal liver enzyme levels	Liver involvement in IEMs, including small molecule disorders (urea cycle disorders, organic acidurias), complex molecule disorders (lysosomal storage disorders, peroxisomal biogenesis disorders), and mitochondrial disorders
Kidney function tests	Abnormal creatinine levels	Elevated level: Renal involvement in IEMs Reduced levels: Creatine synthetic or transporter defect
Uric acid	Abnormal levels	Elevated levels: Disorders of purine metabolism (eg, hypoxanthine-guanine phosphoribosyltransferase deficiency) and gluconeogenesis Reduced levels: Xanthine and hypoxanthine disorders or molybdenum cofactor deficiency
Creatine kinase	Elevated levels	IEMs affecting the muscles, including fatty acid oxidation disorders, gluconeogenesis defects, and mitochondrial disorders
Lipid profile	Dyslipidemia	Glycogen storage diseases, lipoprotein disorders, Wolman disease, disorders of gluconeogenesis

First-Tier testing

In patients with suspected small molecule IEMs, initial targeted investigations should include plasma ammonia, blood glucose, lactate, bicarbonate, blood pH, urine ketones, and urine reducing substances, commonly remembered by the mnemonic GELAK. These investigations are most informative when samples are collected during an episode of metabolic decompensation and preferably before initiation of treatment. However, treatment should not be delayed if timely sample collection is not feasible. Proper sample collection and handling, particularly for lactate and ammonia, are essential to avoid spurious results. Table 5 summarizes the biochemical profiles that can help differentiate major groups of small-molecule IEMs.

Table 5. Metabolic Profiles Across Major Groups of Small-Molecule Inborn Errors of Metabolism

Disorders	Ammonia level	Glucose level	Ketone levels	Lactate levels	Blood gas analysis
Aminoacidopathies	Within reference range	Within reference range	Within reference range	Within reference range	Within reference range
Urea cycle disorders	Markedly elevated	Within reference range	Within reference range	Within reference range	Respiratory alkalosis ±
Maple syrup urine disease	Within reference range	Reduced or within reference range	Elevated	Within reference range	Within reference range
Organic acidemias	Elevated or within reference range	Reduced or within reference range	Elevated	Within reference range	HAGMA
Fatty acid oxidation disorders	Elevated or within reference range	Reduced or within reference range	Reduced/Absent	Markedly elevated	HAGMA
Disorders of ketogenesis	Elevated or within reference range	Reduced or within reference range	Reduced/Absent	Elevated	HAGMA
Disorders of gluconeogenesis	Elevated or within reference range	Markedly reduced	Elevated or within reference range	Elevated	HAGMA

Abbreviation: HAGMA, high anion gap metabolic acidosis.

Certain traditional bedside biochemical tests, such as 2,4-dinitrophenylhydrazine, ferric chloride, nitrosonaphthol, cyanide nitroprusside, and sulfite tests, were historically used to identify specific aminoacidopathies, organic acidemias, and purine metabolism disorders.[12] Although largely obsolete because of advances in specialized biochemical and molecular diagnostics, these tests may still serve as simple bedside tools in resource-limited settings.

Neuroradiology: Neuroimaging, particularly MRI and magnetic resonance spectroscopy (MRS), provides important diagnostic clues in patients with neurological manifestations of IEMs. Imaging findings vary depending on the severity and duration of injury, brain maturity at the time of insult, compensatory mechanisms, and the stage of disease at imaging. Certain anatomical structures demonstrate selective vulnerability to specific toxic metabolites, thereby narrowing the differential diagnosis to particular groups of IEMs.[13] Characteristic neuroimaging findings observed in selected IEMs are summarized in Table 6.

Table 6. Characteristic MRI and Magnetic Resonance Spectroscopy Findings

Disorder	MRI/MRS finding
Maple syrup urine disease	MRI: Edema involving the cerebrum, cerebellum, and brainstem MRS: Branched-chain amino acid and branched-chain ketoacid peaks
Glutaric Aciduria type I	MRI: Open operculum; widened Sylvian fissures and frontotemporal subarachnoid spaces; basal ganglia lesions; white matter abnormalities; and subdural hemorrhage
Nonketotic hyperglycinemia	MRI: Diffusion restriction involving the posterior limb of the internal capsule, anterior brainstem, posterior tegmental tracts, and cerebellum, followed by diffusion restriction in the supratentorial white matter. Hypoplasia of the corpus callosum and cerebral and cerebellar atrophy may occur later in life MRS: Glycine peak
Propionic acidemia and methylmalonic acidemia	MRI: Basal ganglia lesions, delayed myelination, white matter changes, cerebral and cerebellar atrophy, and cerebellar hemorrhage. Cortical and subcortical diffusion restriction may occur in some patients. MRS: Reduced myo-inositol and N-acetylaspartate peaks and abnormal glutamine-glutamate complex peaks in the basal ganglia
Urea cycle defects	MRI: Cortical and subcortical lesions, usually with sparing of the thalamus
Molybdenum cofactor deficiency, sulfite oxidase deficiency	MRI: Diffusion restriction throughout the cortical ribbon, subcortical white matter, basal ganglia, midbrain, and, to a lesser extent, the pons and medulla, followed by atrophy. Cavitary leukomalacia and ulegyria may occur in the chronic state MRS: Lactate doublet and glutamine-glutamate complex peak
*Mitochondrial disorders, including mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes, and POLG-related disorders*	MRI: Nonterritorial cortical and subcortical edema MRS: Elevated lactate peak
Lysosomal storage diseases	GM2 gangliosidoses: T2-weighted signal hypointensity in the ventral thalami and T2-weighted signal hyperintensity in the basal ganglia and dorsal thalami Krabbe disease: Diffuse T2-weighted signal hypointensity in the thalami extending to the corticospinal tracts, signal abnormalities in the cerebral and cerebellar white matter, and variable enlargement of the optic nerve and chiasm Neuronal ceroid lipofuscinosis: T2-weighted signal hypointensity in the thalami with cortical and cerebellar atrophy Metachromatic leukodystrophy: Bilateral, symmetric T2-weighted signal hyperintensities in the white matter with a tigroid pattern and sparing of the subcortical U fibers
Disorders of copper metabolism	Menkes disease: Arterial tortuosity involving the circle of Willis, white matter changes, vermian hypoplasia, progressive atrophy, and subdural fluid collections Wilson disease: T1-weighted signal hyperintensity in the globus pallidus with or without involvement of the striatum and upper brainstem
Neurodegeneration with brain iron accumulation	MRI: Symmetric T2-weighted signal hypointensity in the globus pallidus and substantia nigra. Pantothenate kinase-associated neurodegeneration: Peripheral T2-weighted signal hypointensity and central signal hyperintensity in the globus pallidus (eye-of-the-tiger sign)
Peroxisomal disorders	X-linked adrenoleukodystrophy: Confluent, symmetric T2-weighted and fluid-attenuated inversion recovery signal hyperintensities that usually begin in the parieto-occipital white matter and splenium of the corpus callosum, with contrast enhancement (Loes score) Zellweger syndrome: Cortical malformations, germinolytic cysts, white matter abnormalities, and reduced gray and white matter volume
Creatine deficiency syndromes	MRI: Findings within the reference range or nonspecific volume loss MRS: Markedly reduced or absent creatine peaks at 3 and 3.9 ppm
Congenital disorders of glycosylation	MRI: T2-weighted and fluid-attenuated inversion recovery signal hyperintensity in the cerebellum and cerebellar atrophy MRS: Reduced N-acetylaspartate to creatine ratios and increased myo-inositol peaks

Abbreviations: IEM, inborn error of metabolism; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; ppm, parts per million; POLG, DNA polymerase gamma gene.

Second-Tier Testing

Following clinical suspicion of an IEM based on clinical features and first-tier biochemical test results, additional investigations can be performed to confirm the diagnosis. These include advanced diagnostic techniques such as tandem mass spectrometry, ultrahigh-performance liquid chromatography, or high-performance liquid chromatography, ion-exchange chromatography for amino acid quantification, gas chromatography-mass spectrometry for organic acids, specific enzyme assays, and molecular genetic testing.

Tandem mass spectrometry: Tandem mass spectrometry is a highly sensitive and cost-effective technique that uses ionization and fragmentation to identify metabolites by their mass-to-charge ratio, enabling simultaneous detection of multiple metabolites from a dried blood spot sample. The technique is widely used for screening and diagnosis of aminoacidopathies, organic acidemias, urea cycle disorders, and fatty acid oxidation defects through analysis of amino acid and acylcarnitine profiles. However, interpretation may be limited by overlapping metabolic markers, false-positive and false-negative results, and the inability to reliably detect certain disorders, such as mitochondrial diseases, neurotransmitter disorders, and congenital disorders of glycosylation.

Gas chromatography-mass spectrometry: Gas chromatography-mass spectrometry is an analytical technique that combines gas chromatography-based separation with mass spectrometric identification of metabolites and is primarily used to detect organic acids and other nonpolar metabolites. The technique plays an important role in the diagnosis of organic acidemias, aminoacidopathies, fatty acid oxidation defects, and peroxisomal disorders. However, gas chromatography-mass spectrometry requires specialized infrastructure, careful sample preservation and preparation, and expert interpretation of metabolic profiles.

Ultrahigh-performance liquid chromatography and high-performance liquid chromatography: These techniques are used to quantitatively measure specific amino acids in body fluids, such as plasma, serum, urine, or cerebrospinal fluid. Clinicians use these techniques widely to diagnose many amino acid disorders. The selection of a technique depends on the suspected disorder and the available laboratory resources.

Enzyme assays: Enzyme assays remain critical confirmatory tests for several IEMs, particularly lysosomal storage disorders, mitochondrial disorders, galactosemia, and biotinidase deficiency. Depending on the suspected disorder, these assays may require specialized samples, such as leukocytes, plasma, dried blood spots, cultured skin fibroblasts, or frozen liver and muscle tissue. Appropriate sample selection and handling are essential for accurate interpretation.

Biomarkers: Biomarkers are important indicators of disease detection, disease progression, and therapeutic monitoring in several IEMs. Examples include fibroblast growth factor 21 and growth differentiation factor 15, which are emerging biomarkers for mitochondrial disorders, and plasma chitotriosidase, which is commonly used as a first-tier biomarker for Gaucher disease and acid sphingomyelinase deficiency (Niemann–Pick disease types A and B). However, many biomarkers lack disease specificity, and elevated levels may also occur in common conditions, such as infection, inflammation, or other systemic illnesses, necessitating careful clinical interpretation.

Genetic testing: Next-generation sequencing has emerged as the test of choice for diagnosing IEMs, driven by decreasing costs, widespread availability, and the convenience of using readily available samples, such as blood. The untargeted approach allows simultaneous sequencing of multiple genes, providing a comprehensive genetic analysis without the influence of external factors that often affect the accuracy of advanced metabolic tests. Moreover, next-generation sequencing facilitates the interpretation of genetic findings by leveraging the availability of biochemical biomarkers commonly associated with IEMs. These biomarkers help correlate detected genetic variants with their clinical significance, supporting a more precise diagnosis. By integrating genetic and biochemical data, next-generation sequencing enhances the diagnostic yield, making it a cornerstone in the evaluation of complex metabolic conditions.

Treatment / Management

For small molecule IEMs presenting with acute metabolic decompensation, treatment focuses on rapid stabilization during a crisis and long-term strategies aimed at preventing recurrence.

Acute Management

Acute treatment follows the principle of suspend, support, and scavenge.

Supportive care: Initial treatment is directed toward stabilizing the airway, breathing, circulation, and temperature, and correcting electrolyte abnormalities. Associated complications, such as sepsis and seizures, should be treated promptly. Clinicians should preferably avoid sodium valproate because of its mitochondrial toxicity and risk of worsening hyperammonemia.
Suspend intake of toxic substrates: In suspected intoxication-type disorders, oral intake of potential toxic substrates, such as protein, galactose, or fructose, should be immediately discontinued.
Support anabolism: Catabolism should be rapidly reversed by providing high-calorie intravenous fluids, usually 10% dextrose with age-appropriate electrolytes, at approximately 1.5 times the maintenance fluid requirements, targeting a glucose infusion rate of 8 to 10 mg/kg/min. An insulin infusion may be required to control hyperglycemia while maintaining an anabolic state. However, excessive glucose administration and hyperglycemia should be avoided in patients with suspected pyruvate dehydrogenase deficiency or mitochondrial disorders.
Scavenge toxic metabolites: Hyperammonemia should be treated aggressively using nitrogen scavengers, such as sodium benzoate and sodium phenylacetate. Extracorporeal detoxification with hemodialysis or hemodiafiltration should be considered in patients with severe hyperammonemia (typically > 500 to 600 µmol/L) or worsening neurological status.
Management of acidosis: Sodium bicarbonate therapy is generally not indicated unless the serum bicarbonate level is < 10 mmol/L or the arterial pH is < 7.1, particularly if acidosis fails to improve with toxin removal and supportive therapy. Repeated bicarbonate boluses should be avoided because they may precipitate hypernatremia, cerebral edema, and intracranial hemorrhage.
Cofactors: Empirical administration of metabolic cofactors, such as biotin, thiamine, vitamin B₁₂, and riboflavin, is commonly initiated while awaiting diagnostic confirmation.[14]
Nutritional support: Patients should not go without oral intake for more than 24 to 48 hours. Once clinically stable, patients should gradually resume enteral feeding with disease-specific dietary modifications, such as low-protein or specialized formulas. If enteral nutrition cannot be established within 24 to 48 hours, parenteral nutrition, including intravenous lipids (except in patients with fatty acid oxidation defects), should be initiated with close monitoring of triglyceride levels.[15]

Long-Term Treatment

Long-term management aims to prevent metabolic decompensation, minimize toxic metabolite accumulation, and improve overall quality of life.

Dietary therapy and metabolic stabilization: Avoidance of metabolic triggers, dietary restriction of specific substrates, and supplementation with cofactors and conditionally essential nutrients remain the cornerstone of therapy for many small-molecule disorders. For example, treatment of phenylketonuria includes a phenylalanine-restricted diet along with large-neutral-amino-acid- or glycomacropeptide-based formulations.[16] Table 7 summarizes long-term treatment strategies for selected small-molecule IEMs.
Enzyme replacement therapy: Enzyme replacement therapy involves administering a functional exogenous enzyme that is taken up by deficient cells, particularly within lysosomes, thereby reducing substrate accumulation. Approved therapies are available for several lysosomal storage disorders, including Gaucher disease, Pompe disease, Fabry disease, mucopolysaccharidoses (types 1, 2, 4A, and 6), α-mannosidosis, lysosomal acid lipase deficiency, and acid sphingomyelinase deficiency.
Substrate reduction therapy: Substrate reduction therapy aims to reduce the synthesis of toxic metabolites and thereby prevent substrate accumulation. Currently available therapies include eliglustat and miglustat for Gaucher disease, miglustat and arimoclomol for Niemann–Pick disease type C, and nitisinone for hereditary tyrosinemia type 1.
Hematopoietic stem cell and bone marrow transplantation: Hematopoietic stem cell transplant and bone marrow transplant are based on the principle of cross-correction, in which donor-derived healthy cells provide a continuous source of the deficient enzyme. Hematopoietic stem cell transplant is considered the standard of care for selected disorders, such as presymptomatic Krabbe disease, mucopolysaccharidosis type 1 (especially before age 2 years), α-mannosidosis, and leukodystrophies, including X-linked adrenoleukodystrophy and metachromatic leukodystrophy.
Pharmacological chaperone therapy: Pharmacological chaperones are small molecules that stabilize misfolded enzymes, facilitate their trafficking from the endoplasmic reticulum to lysosomes, and improve residual enzymatic activity. Approved examples include migalastat for Fabry disease and the combination of cipaglucosidase alfa with miglustat for late-onset Pompe disease.[17]
Gene and cellular therapies: Gene therapy involves the delivery of a functional copy of the defective gene using nonreplicating viral vectors. Approved therapies currently include therapies for aromatic L-amino acid decarboxylase (AADC) deficiency and metachromatic leukodystrophy.[18][19] Gene and cellular therapies represent a rapidly evolving frontier in the treatment of inherited metabolic disorders.[20]

(B2)

Table 7. Long-Term Treatment for Small-Molecule Inborn Errors of Metabolism

Group of disorders	Treatment modalities
Fatty acid oxidation disorders	Avoidance of fasting: Avoid fasting, including overnight fasting. Dietary restrictions: Dietary restriction is not required in medium-chain acyl-coenzyme A dehydrogenase deficiency. Restriction of long-chain fats is recommended in severe long-chain fatty acid oxidation disorders. Medium-chain triglycerides are contraindicated in medium-chain acyl-coenzyme A dehydrogenase, electron transfer flavoprotein, and electron transfer flavoprotein ubiquinone oxidoreductase deficiencies. Pharmacotherapies and supplements: Medium-chain triglyceride supplementation in severe long-chain fatty acid oxidation disorders (approximately 20% of energy intake from medium-chain triglycerides and 10% from long-chain fats) Triheptanoin (25% to 35% of daily caloric intake) may be used instead of medium-chain triglycerides in long-chain fatty acid oxidation disorders Docosahexaenoic acid supplementation in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase and trifunctional protein deficiencies Carnitine supplementation for carnitine transporter deficiency; its role in other fatty acid oxidation disorders is controversial and may be harmful in long-chain fatty acid oxidation disorders Riboflavin supplementation in multiple acyl-coenzyme A dehydrogenase deficiency Vitamin and mineral supplementation Coenzyme Q10 supplementation when concomitant primary or secondary mitochondrial involvement is suspected (eg, multiple acyl-coenzyme A dehydrogenase deficiency)
Disorders of gluconeogenesis	Avoidance of fasting: Avoid fasting, particularly during illness. Dietary restrictions: • Restrict fat to 20% to 25% and protein to 10% of energy requirements.• Restrict fructose, sucrose, and sorbitol in glucose-6-phosphatase and fructose-1,6-bisphosphatase deficiencies. Pharmacotherapies and supplements: • Uncooked cornstarch to prevent hypoglycemia, especially nocturnal hypoglycemia• Citrate and aspartate supplementation in pyruvate carboxylase deficiency• Vitamin and mineral supplementationOrthotopic liver transplant: Consider in refractory cases.
Disorders of ketogenesis and ketone body utilization	Avoidance of fasting: Avoid fasting and maintain a high-carbohydrate intake during metabolic stress Dietary restrictions: Moderate protein restriction in β-ketothiolase deficiency and 3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency Pharmacotherapies and supplements: Carnitine supplementation
Organic acidemias	Treatment during acute decompensation: Withhold protein and provide a high-carbohydrate diet for 12 to 48 hours. Avoidance of constipation: Avoid constipation, particularly in methylmalonic acidemia and propionic acidemia. Dietary restrictions: • Protein-restricted diet using precursor-free amino acid mixtures with adequate natural protein intake (approximately two-thirds of the requirement) in propionic acidemia, methylmalonic acidemia, and occasionally isovaleric acidemia.• Low-lysine with or without low-tryptophan diet in glutaric aciduria type 1. Pharmacotherapies and supplements: • Carnitine supplementation.• Intramuscular hydroxocobalamin in selected vitamin B₁₂-responsive forms of methylmalonic acidemia.• Biotin supplementation in selected patients.• Intermittent metronidazole prophylaxis in propionic acidemia.• Treatment of chronic hyperammonemia where indicated.• Standard antidystonia therapies in glutaric aciduria type 1.• Supplementation of essential vitamins and minerals
Urea cycle disorders	Dietary restrictions: Low-protein diet adjusted to World Health Organization safe levels of intake, with essential amino acid supplementation (30% to 50% of protein intake) when protein tolerance is poor. Pharmacotherapies and supplements: Nitrogen scavengers: sodium benzoate, sodium phenylbutyrate, sodium phenylacetate, glycerol phenylbutyrate, and carglumic acid L-arginine and L-citrulline supplementation (except in arginase deficiency) Carnitine supplementation in secondary carnitine deficiency Vitamin and mineral supplementation Liver transplant: Consider liver transplant (except in N-acetylglutamate synthase deficiency) in severely affected individuals as an alternative to long-term dietary therapy.

Differential Diagnosis

The differential diagnosis for IEMs is broad and frequently overlaps with common pediatric emergencies. Important differential diagnoses include:

Sepsis: Poor feeding, lethargy, shock, metabolic acidosis, hyperammonemia, and culture-negative illness may mimic neonatal sepsis
Cardiac disorders: Cardiomyopathy, arrhythmias, shock, lactic acidosis, and acute decompensation may resemble metabolic disease
Gastrointestinal tract disorders: Recurrent vomiting, dehydration, failure to thrive, liver dysfunction, or metabolic alkalosis or acidosis may simulate the presentation of an IEM
Neurological disorders: Encephalopathy, seizures, hypotonia, coma, developmental regression, or stroke-like episodes may overlap with metabolic disorders
Endocrine disorders: Hypoglycemia, ketosis, electrolyte disturbances, liver dysfunction, or recurrent metabolic crises may resemble IEMs
Toxic ingestion: Altered sensorium, high anion gap metabolic acidosis, liver dysfunction, or hyperammonemia may mimic intoxication-type IEMs
Hematological disorders: Cytopenias, hepatosplenomegaly, recurrent infections, or hemophagocytic syndromes may resemble lysosomal or mitochondrial disorders
Renal disorders: Metabolic acidosis, electrolyte imbalance, nephrolithiasis, or renal failure may resemble manifestations of several IEMs
Respiratory tract disorders: Apnea, respiratory distress, persistent lactic acidosis, or unexplained respiratory failure may resemble metabolic decompensation

A high index of suspicion for IEM is warranted in infants or children with recurrent unexplained encephalopathy, metabolic acidosis, hyperammonemia, hypoglycemia, developmental regression, multisystem involvement, or deterioration precipitated by fasting or intercurrent illness.

Prognosis

The prognosis of IEMs is highly variable and depends on the specific disorder, genotype–phenotype correlation, severity of enzymatic dysfunction, and timing of diagnosis and treatment.

Favorable prognosis: Disorders such as phenylketonuria and biotinidase deficiency have excellent outcomes when identified early through newborn screening and treated promptly, with many patients achieving normal growth, neurodevelopment, and life expectancy.[21] Certain lysosomal storage disorders, including Gaucher disease type 1 and some mucopolysaccharidoses, are also associated with improved survival and quality of life with early initiation of enzyme replacement therapy or hematopoietic stem cell transplant.

Guarded: Disorders such as urea cycle defects, organic acidemias, and some treatable lysosomal or peroxisomal disorders may still be associated with recurrent metabolic decompensation, neurocognitive impairment, chronic kidney disease, cardiomyopathy, or progressive multisystem involvement despite treatment.[22]

Poor: Severe mitochondrial disorders (eg, Leigh syndrome), rapidly progressive neurodegenerative lysosomal storage disorders, and many complex molecule disorders with congenital multisystem involvement are often associated with significant neurological decline, loss of developmental milestones, and early mortality.[23]

Complications

Untreated or severe IEMs can result in significant multisystem complications involving the central nervous system, liver, heart, kidneys, and nutritional status.

Neurological complications: Progressive neurodegeneration leading to intellectual disability, developmental regression, refractory epilepsy, dystonia or spasticity, cerebral palsy–like sequelae, cortical blindness, sensorineural hearing loss, and permanent motor impairment
Hepatic complications: Progressive fibrosis and cirrhosis, portal hypertension, acute or chronic liver failure, and hepatocellular carcinoma, particularly in hereditary tyrosinemia type 1
Cardiac complications: Progressive dilated or hypertrophic cardiomyopathy, arrhythmias, conduction defects, and eventual heart failure, especially in disorders such as Pompe disease and fatty acid oxidation defects
Renal complications: Chronic kidney disease, nephrocalcinosis, recurrent nephrolithiasis, and end-stage kidney disease, particularly in hereditary tyrosinemia type 1, methylmalonic acidemia, and primary hyperoxaluria
Musculoskeletal complications: Severe osteopenia or osteoporosis, pathological fractures, contractures, scoliosis, progressive myopathy, and loss of ambulation
Respiratory complications: Recurrent aspiration, restrictive lung disease, chronic respiratory insufficiency, sleep-disordered breathing, and respiratory failure
Nutritional and growth-related: Severe failure to thrive, growth retardation, micronutrient deficiencies, feeding intolerance, and long-term dependence on enteral feeding support such as gastrostomy tubes

Deterrence and Patient Education

Preventive and educational strategies for IEMs should focus on early identification, counseling on recurrence risk, and preventing metabolic decompensation. Key aspects include:

Genetic counseling: Genetic counseling is essential for families with an affected child to understand inheritance patterns, recurrence risks (commonly 25% in autosomal recessive disorders), and available reproductive options such as carrier testing, prenatal diagnosis, and preimplantation genetic testing.
Newborn screening: Parents should be educated regarding the importance of newborn screening, early diagnosis, and the need for prompt follow-up when screening results are abnormal or positive.
Emergency protocols: Families should be provided with a written emergency protocol or letter detailing the diagnosis and immediate management steps during acute illness, such as initiating intravenous dextrose-containing fluids and avoiding prolonged fasting, to facilitate timely intervention by emergency healthcare professionals.
Dietary adherence and sick-day plans: Caregivers should receive detailed education regarding dietary restrictions, preparation of specialized medical formulas, interpretation of food labels, sick-day plans, and early recognition of warning signs of metabolic decompensation, including poor feeding, vomiting, lethargy, altered sensorium, or seizures.

Enhancing Healthcare Team Outcomes

Treatment of IEMs requires a coordinated interdisciplinary approach to optimize clinical outcomes, minimize complications, and improve quality of life.

Medical geneticist/biochemical geneticist: Leads the diagnostic evaluation, coordinates metabolic investigations, establishes the molecular diagnosis, and formulates individualized treatment plans.
Metabolic dietitian: Plays a central role in designing specialized therapeutic diets, monitoring nutritional status and growth, ensuring dietary adherence, and preventing micronutrient deficiencies.
Primary care clinician and pediatrician: Monitor overall health, growth, development, and immunization status, and recognize early signs of metabolic decompensation during intercurrent illnesses.
Emergency clinicians and intensivists: Must promptly recognize potential metabolic crises, initiate emergency metabolic protocols without delay, and maintain a high index of suspicion for IEMs in children presenting with unexplained encephalopathy, metabolic acidosis, hyperammonemia, recurrent vomiting, hypoglycemia, or multisystem involvement.
Social workers and psychologists: Provide psychosocial support to patients and caregivers, assist with access to medical foods and therapies, facilitate insurance or financial support, and aid transition from pediatric to adult care services.
Subspecialists: Multisystem involvement often necessitates collaboration with cardiology, neurology, hepatology, gastroenterology, nephrology, endocrinology, pulmonology, ophthalmology, rehabilitation medicine, and palliative care teams to monitor and treat disease-related complications.
Laboratory specialists and genetic counselors: Biochemical laboratories, molecular diagnostic teams, and genetic counselors are essential for timely diagnosis, interpretation of complex results, cascade screening, and family counseling regarding recurrence risk and reproductive options.

Effective communication among healthcare professionals, supported by individualized comprehensive care plans and emergency protocols, significantly reduces morbidity, hospital admissions, and mortality while improving long-term patient outcomes and quality of life.

References

[1]

Morava E, Rahman S, Peters V, Baumgartner MR, Patterson M, Zschocke J. Quo vadis: the re-definition of "inborn metabolic diseases". Journal of inherited metabolic disease. 2015 Nov:38(6):1003-6. doi: 10.1007/s10545-015-9893-x. Epub 2015 Sep 29 [PubMed PMID: 26420281]

[2]

Ferreira CR, van Karnebeek CDM, Vockley J, Blau N. A proposed nosology of inborn errors of metabolism. Genetics in medicine : official journal of the American College of Medical Genetics. 2019 Jan:21(1):102-106. doi: 10.1038/s41436-018-0022-8. Epub 2018 Jun 8 [PubMed PMID: 29884839]

[3]

Waters D, Adeloye D, Woolham D, Wastnedge E, Patel S, Rudan I. Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. Journal of global health. 2018 Dec:8(2):021102. doi: 10.7189/jogh.08.021102. Epub [PubMed PMID: 30479748]

Level 1 (high-level) evidence

[4]

Rutten MGS, Rots MG, Oosterveer MH. Exploiting epigenetics for the treatment of inborn errors of metabolism. Journal of inherited metabolic disease. 2020 Jan:43(1):63-70. doi: 10.1002/jimd.12093. Epub 2019 Apr 22 [PubMed PMID: 30916397]

[5]

Wang D, Zhang J, Yang R, Zhang D, Wang M, Yu C, Yang J, Huang W, Liu S, Tang S, He X. Disease spectrum, prevalence, genetic characteristics of inborn errors of metabolism in 21,840 hospitalized infants in Chongqing, China, 2017-2022. Frontiers in genetics. 2024:15():1395988. doi: 10.3389/fgene.2024.1395988. Epub 2024 May 28 [PubMed PMID: 38863445]

Level 2 (mid-level) evidence

[6]

Walter J. IEMs in adults. Journal of inherited metabolic disease. 2007 Oct:30(5):627 [PubMed PMID: 17891476]

[7]

Sirrs S, Hollak C, Merkel M, Sechi A, Glamuzina E, Janssen MC, Lachmann R, Langendonk J, Scarpelli M, Ben Omran T, Mochel F, SFEIM-A Study Group, Tchan MC. The Frequencies of Different Inborn Errors of Metabolism in Adult Metabolic Centres: Report from the SSIEM Adult Metabolic Physicians Group. JIMD reports. 2016:27():85-91. doi: 10.1007/8904_2015_435. Epub 2015 Oct 9 [PubMed PMID: 26450566]

[8]

Saudubray JM, Mochel F, Lamari F, Garcia-Cazorla A. Proposal for a simplified classification of IMD based on a pathophysiological approach: A practical guide for clinicians. Journal of inherited metabolic disease. 2019 Jul:42(4):706-727. doi: 10.1002/jimd.12086. Epub 2019 Apr 24 [PubMed PMID: 30883825]

[9]

Guibaud L, Collardeau-Frachon S, Lacalm A, Massoud M, Rossi M, Cordier MP, Vianey-Saban C. Antenatal manifestations of inborn errors of metabolism: prenatal imaging findings. Journal of inherited metabolic disease. 2017 Jan:40(1):103-112. doi: 10.1007/s10545-016-9992-3. Epub 2016 Nov 16 [PubMed PMID: 27853988]

[10]

Sedel F, Baumann N, Turpin JC, Lyon-Caen O, Saudubray JM, Cohen D. Psychiatric manifestations revealing inborn errors of metabolism in adolescents and adults. Journal of inherited metabolic disease. 2007 Oct:30(5):631-41 [PubMed PMID: 17694356]

[11]

Koens LH, de Vries JJ, Vansenne F, de Koning TJ, Tijssen MAJ. How to detect late-onset inborn errors of metabolism in patients with movement disorders - A modern diagnostic approach. Parkinsonism & related disorders. 2021 Apr:85():124-132. doi: 10.1016/j.parkreldis.2021.02.029. Epub 2021 Mar 2 [PubMed PMID: 33745796]

[12]

Bijarnia-Mahay S, Kapoor S. Testing Modalities for Inborn Errors of Metabolism - What a Clinician Needs to Know? Indian pediatrics. 2019 Sep 15:56(9):757-766 [PubMed PMID: 31638009]

[13]

Lai LM, Gropman AL, Whitehead MT. MR Neuroimaging in Pediatric Inborn Errors of Metabolism. Diagnostics (Basel, Switzerland). 2022 Mar 30:12(4):. doi: 10.3390/diagnostics12040861. Epub 2022 Mar 30 [PubMed PMID: 35453911]

[14]

Breilyn MS, Wasserstein MP. Established and Emerging Treatments for Patients with Inborn Errors of Metabolism. NeoReviews. 2020 Oct:21(10):e699-e707. doi: 10.1542/neo.21-10-e699. Epub [PubMed PMID: 33004565]

[15]

Kripps KA, Baker PR 2nd, Thomas JA, Skillman HE, Bernstein L, Gaughan S, Burns C, Coughlin CR 2nd, McCandless SE, Larson AA, Kochar A, Stillman CF, Wymore EM, Hendricks EG, Woontner M, Van Hove JLK. REVIEW: Practical strategies to maintain anabolism by intravenous nutritional management in children with inborn metabolic diseases. Molecular genetics and metabolism. 2021 Jul:133(3):231-241. doi: 10.1016/j.ymgme.2021.04.007. Epub 2021 May 7 [PubMed PMID: 33985889]

[16]

Singh RH, Cunningham AC, Mofidi S, Douglas TD, Frazier DM, Hook DG, Jeffers L, McCune H, Moseley KD, Ogata B, Pendyal S, Skrabal J, Splett PL, Stembridge A, Wessel A, Rohr F. Updated, web-based nutrition management guideline for PKU: An evidence and consensus based approach. Molecular genetics and metabolism. 2016 Jun:118(2):72-83. doi: 10.1016/j.ymgme.2016.04.008. Epub 2016 Apr 17 [PubMed PMID: 27211276]

Level 3 (low-level) evidence

[17]

Matalonga L, Gort L, Ribes A. Small molecules as therapeutic agents for inborn errors of metabolism. Journal of inherited metabolic disease. 2017 Mar:40(2):177-193. doi: 10.1007/s10545-016-0005-3. Epub 2016 Dec 13 [PubMed PMID: 27966099]

[18]

Roubertie A, Opladen T, Brennenstuhl H, Kuseyri Hübschmann O, Flint L, Willemsen MA, Leuzzi V, Cazorla AG, Kurian MA, François-Heude MC, Hwu P, Zeev BB, Kiening K, Roujeau T, Pons R, Pearson TS. Gene therapy for aromatic L-amino acid decarboxylase deficiency: Requirements for safe application and knowledge-generating follow-up. Journal of inherited metabolic disease. 2024 May:47(3):463-475. doi: 10.1002/jimd.12649. Epub 2023 Jul 17 [PubMed PMID: 37402126]

[19]

Horgan C, Watts K, Ram D, Rust S, Hutton R, Jones S, Wynn R. A retrospective cohort study of Libmeldy (atidarsagene autotemcel) for MLD: What we have accomplished and what opportunities lie ahead. JIMD reports. 2023 Sep:64(5):346-352. doi: 10.1002/jmd2.12378. Epub 2023 Jun 22 [PubMed PMID: 37701322]

Level 2 (mid-level) evidence

[20]

Gambello MJ, Li H. Current strategies for the treatment of inborn errors of metabolism. Journal of genetics and genomics = Yi chuan xue bao. 2018 Feb 20:45(2):61-70. doi: 10.1016/j.jgg.2018.02.001. Epub 2018 Feb 14 [PubMed PMID: 29500085]

[21]

Canton M, Gall DL, Feillet F, Bonnemains C, Roy A. Neuropsychological Profile of Children with Early and Continuously Treated Phenylketonuria: Systematic Review and Future Approaches. Journal of the International Neuropsychological Society : JINS. 2019 Jul:25(6):624-643. doi: 10.1017/S1355617719000146. Epub 2019 Apr 29 [PubMed PMID: 31030702]

Level 1 (high-level) evidence

[22]

Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Lichter-Konecki U, Caldovic L, Morizono H, Simpson K, Ah Mew N, MacLeod E. Ornithine Transcarbamylase Deficiency. GeneReviews(®). 1993:(): [PubMed PMID: 24006547]

[23]

van de Wal MAE, Adjobo-Hermans MJW, Keijer J, Schirris TJJ, Homberg JR, Wieckowski MR, Grefte S, van Schothorst EM, van Karnebeek C, Quintana A, Koopman WJH. Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention. Brain : a journal of neurology. 2022 Mar 29:145(1):45-63. doi: 10.1093/brain/awab426. Epub [PubMed PMID: 34849584]